FDA Approves First Generic Versions of FARXIGA - Top-Institutions - MDSpire

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

  • By

  • Kathryn Wighton

  • April 7, 2026

  • 2 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Cardiology
    • Clinical Research

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Endocrinology
    • Cardiology
    • Pharmacology

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Endocrinology
    • Cardiology
    • Clinical Pharmacology

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Endocrinology
    • Clinical Research

  • #5

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Cardiology
    • Clinical Trials

Original Source(s)

FDA Approves First Generic Versions of FARXIGA

  • by Kathryn Wighton

  • April 7, 2026

Related Content

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Exposure to heavy metals and trace elements and risk of dyslipidemia: a nested case-control analysis in rural adults

Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis